Semaglyn in India

What is Semaglyn?

Semaglyn is a brand of semaglutide marketed in India by Zydus Lifesciences. Semaglutide belongs to a class of medicines called GLP-1 receptor agonists — drugs that mimic a natural gut hormone (GLP-1) that helps the body manage blood sugar and appetite.

Semaglutide is generally prescribed for:

• Type 2 diabetes, to help improve blood sugar control, often alongside other medicines like metformin.
• Chronic weight management in adults with obesity, or who are overweight with related health conditions such as high blood pressure, high cholesterol, or type 2 diabetes.

The exact approved use of Semaglyn in India depends on its CDSCO approval and your doctor's clinical judgement.

How is it taken?

Semaglutide is most commonly available as a once-weekly injection given under the skin (subcutaneous) of the stomach, thigh, or upper arm using a pre-filled pen. An oral (tablet) form of semaglutide also exists globally; the specific presentation of Semaglyn available to you will be confirmed by your pharmacist and prescription.

Who is it for?

In Indian clinical practice, GLP-1 medicines like semaglutide are typically considered for adults whose blood sugar is not adequately controlled on oral diabetes medicines, or for adults needing medical support for weight management as part of a broader plan including diet and physical activity. It is not a first-line medicine for everyone, and it is not suitable for certain people (for example, those with a personal or family history of medullary thyroid cancer).

Always consult your doctor before starting or changing any GLP-1 medication.

Who makes Semaglyn?

Semaglyn is manufactured and marketed in India by Zydus Lifesciences, one of India's large pharmaceutical companies headquartered in Ahmedabad.

Semaglyn is a Zydus Lifesciences generic version of semaglutide. Semaglutide as a molecule was originally developed by a different originator company; Semaglyn is not the originator brand. It is offered as an Indian generic alternative containing the same active ingredient.

Regulatory status

Medicines containing semaglutide marketed in India, including Semaglyn, fall under the regulatory oversight of the Central Drugs Standard Control Organisation (CDSCO), India's national drug regulator. Your prescribing doctor and pharmacist can confirm the specific approved indications and presentations available locally.

Prices vary across Indian pharmacies — see the price comparator inside Glipin for current listings. Glipin does not endorse any manufacturer and does not receive payment from Zydus Lifesciences for this listing.

Typical titration schedule

Semaglutide is almost always started at a low dose and slowly increased over several weeks. This is called titration, and it is done to reduce side effects — mainly nausea — while your body gets used to the medicine.

A typical once-weekly injectable semaglutide pattern looks like this:

• Weeks 1–4: A low starting dose, used mainly to let the body adjust. This dose is generally not enough to fully control blood sugar or drive weight loss on its own.
• Weeks 5–8: The dose is stepped up to the next level.
• Further escalation every ~4 weeks: The dose is increased gradually, with each step held for around 4 weeks before going higher.
• Maintenance dose: Once an effective and well-tolerated dose is reached, that becomes the ongoing weekly dose.

For type 2 diabetes and weight management, the typical maintenance doses can differ, and the maximum approved dose also differs by indication and by product. If side effects appear at any step, doctors often hold the current dose longer, or step back down temporarily, before trying to increase again.

This page shows the typical pattern only. It is not a prescription.

Your prescribing doctor will set your exact dose based on your response and any side effects.

Common side effects

Most side effects of semaglutide come from how it slows the stomach and reduces appetite. The most frequently reported ones in everyday language are:

• Nausea — feeling sick, especially in the first few days after a dose increase.
• Decreased appetite and feeling full quickly during meals.
• Vomiting in some people, usually mild.
• Diarrhoea or, conversely, constipation.
• Burping, bloating, or indigestion.
• Tiredness during the initial weeks.
• Mild injection-site reactions — small redness or itching where the pen was used.

These effects are usually mild and tend to improve over a few weeks as the body adjusts, and are often worst right after a dose step-up. Many people find that eating smaller meals, eating more slowly, and avoiding very oily or heavy food makes the early weeks easier. Some people experience minor changes in taste or a slight reduction in how much they enjoy rich foods.

Less commonly, people report gallbladder-related discomfort, dizziness, or changes in blood sugar (especially if combined with other diabetes medicines such as insulin or sulfonylureas).

When to seek medical help

Contact your doctor immediately if you experience severe or persistent abdominal pain (especially pain that radiates to the back, which can be a sign of pancreatitis), persistent vomiting or inability to keep fluids down, signs of an allergic reaction (rash, swelling of the face or throat, difficulty breathing), severe pain in the upper right abdomen (possible gallbladder problem), signs of very low blood sugar, or any sudden vision changes. Do not stop or change your dose without medical advice.